[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100573559":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":32,"centralContacts":33,"locations":39,"responsibleParty":176,"collaborators":32,"id":178,"slug":179,"hasResults":180,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":180,"sex":186,"minAge":187,"maxAge":32,"enrollmentInfo":188,"targetDuration":32,"studyType":191,"phases":192,"briefSummary":194,"conditions":195,"keywords":198,"overallStatus":42,"whyStopped":32,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":210},{"fullName":5,"class":6},"Arcturus Therapeutics, Inc.","INDUSTRY",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1","EXPERIMENTAL","Dose Level A of ARCT-032, inhaled daily for 28 days",[13],"Biological: ARCT-032",{"label":15,"type":10,"description":16,"interventionNames":17},"Cohort 2","Dose Level B of ARCT-032, inhaled daily for 28 days",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cohort 3","Dose Level C of ARCT-032, inhaled daily for 28 days",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Cohort 4","Dose level B or C of ARCT-032, inhaled once daily for 12 weeks",[13],[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"BIOLOGICAL","ARCT-032","CFTR mRNA formulated in lipid nanoparticles",[9,15,19,23],null,[34],{"name":35,"role":36,"phone":37,"phoneExt":32,"email":38},"Clinical Trial Disclosure Manager Central Email Box","CONTACT","858-900-2660","CFclinicaltrials@arcturusrx.com",[40,54,64,74,85,95,106,116,126,136,146,156,166],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":32},"University of Arizona","RECRUITING","Tucson","Arizona","85724","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-110.92648,32.22174,{"lat":52,"lon":51},{"facility":55,"status":42,"city":56,"state":57,"zip":58,"country":46,"countryCode":47,"cosmosGeoPoint":59,"geoPoint":63,"contacts":32},"University of Arkansas for Medical Sciences","Little Rock","Arkansas","72205",{"type":49,"coordinates":60},[61,62],-92.28959,34.74648,{"lat":62,"lon":61},{"facility":65,"status":42,"city":66,"state":67,"zip":68,"country":46,"countryCode":47,"cosmosGeoPoint":69,"geoPoint":73,"contacts":32},"Children's Hospital of Los Angeles","Los Angeles","California","90027",{"type":49,"coordinates":70},[71,72],-118.24368,34.05223,{"lat":72,"lon":71},{"facility":75,"status":76,"city":77,"state":78,"zip":79,"country":46,"countryCode":47,"cosmosGeoPoint":80,"geoPoint":84,"contacts":32},"Children's National Hospital","NOT_YET_RECRUITING","Washington D.C.","District of Columbia","20010",{"type":49,"coordinates":81},[82,83],-77.03637,38.89511,{"lat":83,"lon":82},{"facility":86,"status":42,"city":87,"state":88,"zip":89,"country":46,"countryCode":47,"cosmosGeoPoint":90,"geoPoint":94,"contacts":32},"Joe DiMaggio Children's Hospital","Hollywood","Florida","33021",{"type":49,"coordinates":91},[92,93],-80.14949,26.0112,{"lat":93,"lon":92},{"facility":96,"status":97,"city":98,"state":99,"zip":100,"country":46,"countryCode":47,"cosmosGeoPoint":101,"geoPoint":105,"contacts":32},"The Cystic Fibrosis Institute","ACTIVE_NOT_RECRUITING","Northfield","Illinois","60093",{"type":49,"coordinates":102},[103,104],-87.7809,42.09975,{"lat":104,"lon":103},{"facility":107,"status":42,"city":108,"state":109,"zip":110,"country":46,"countryCode":47,"cosmosGeoPoint":111,"geoPoint":115,"contacts":32},"Boston Children's Hospital","Boston","Massachusetts","02115",{"type":49,"coordinates":112},[113,114],-71.05977,42.35843,{"lat":114,"lon":113},{"facility":117,"status":42,"city":118,"state":119,"zip":120,"country":46,"countryCode":47,"cosmosGeoPoint":121,"geoPoint":125,"contacts":32},"Washington University School of Medicine","St Louis","Missouri","63144",{"type":49,"coordinates":122},[123,124],-90.19789,38.62727,{"lat":124,"lon":123},{"facility":127,"status":42,"city":128,"state":129,"zip":130,"country":46,"countryCode":47,"cosmosGeoPoint":131,"geoPoint":135,"contacts":32},"Cleveland Clinic Foundation","Cleveland","Ohio","44195",{"type":49,"coordinates":132},[133,134],-81.69541,41.4995,{"lat":134,"lon":133},{"facility":137,"status":42,"city":138,"state":139,"zip":140,"country":46,"countryCode":47,"cosmosGeoPoint":141,"geoPoint":145,"contacts":32},"Medical University of South Carolina","Charleston","South Carolina","29425",{"type":49,"coordinates":142},[143,144],-79.93275,32.77632,{"lat":144,"lon":143},{"facility":147,"status":42,"city":148,"state":149,"zip":150,"country":46,"countryCode":47,"cosmosGeoPoint":151,"geoPoint":155,"contacts":32},"Vanderbilt University Medical Center","Nashville","Tennessee","37232",{"type":49,"coordinates":152},[153,154],-86.78444,36.16589,{"lat":154,"lon":153},{"facility":157,"status":42,"city":158,"state":159,"zip":160,"country":46,"countryCode":47,"cosmosGeoPoint":161,"geoPoint":165,"contacts":32},"UT Health San Antonio","San Antonio","Texas","78229",{"type":49,"coordinates":162},[163,164],-98.49363,29.42412,{"lat":164,"lon":163},{"facility":167,"status":42,"city":168,"state":169,"zip":170,"country":46,"countryCode":47,"cosmosGeoPoint":171,"geoPoint":175,"contacts":32},"Seattle Children's Hospital","Seattle","Washington","98105",{"type":49,"coordinates":172},[173,174],-122.33207,47.60621,{"lat":174,"lon":173},{"type":177,"investigatorFullName":32,"investigatorTitle":32,"investigatorAffiliation":32,"oldNameTitle":32,"oldOrganization":32},"SPONSOR","100573559","phase-2-safety-tolerability-and-efficacy-study-of-arct-032-in-people-with-cystic-fibrosis-100573559",false,"NCT06747858","Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis","A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ARCT-032 in People With Cystic Fibrosis","LunairCF","Key Inclusion Criteria:\n\n1. Confirmed diagnosis of Cystic Fibrosis\n2. Not eligible for CFTR modulator therapy or not taking CFTR modulators for at least 60 days prior to dosing (e.g. due to intolerance, poor response, or lack of access to modulators)\n3. FEV1 between 40% to 100% (cohorts 1-3) and 45% to 90% (cohort 4, inclusive) of predicted value for age, sex and height\n\nExclusion Criteria:\n\n1. History of illness or medical condition that might pose an additional risk or may confound study results\n2. Recent moderate or severe hemoptysis\n3. Recent major surgery\n4. Solid organ or hematologic transplant\n5. Requirement of supplemental oxygen while awake or \\> 2L per minute while sleeping.\n6. Chronic maintenance systemic corticosteroids exceeding equivalent of daily 15 mg oral prednisone or 30 mg every other day\n7. Adequate liver and kidney function as determined by lab tests","ALL","18 Years",{"count":189,"type":190},33,"ESTIMATED","INTERVENTIONAL",[193],"PHASE2","ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.",[196,197],"Cystic Fibrosis","CFTR Gene Mutation",[199,200],"CFTR","mRNA","2026-05-06",{"date":203,"type":204},"2026-05-08","ACTUAL",{"date":206,"type":204},"2024-12-12",{"date":208,"type":190},"2027-06",{"name":5,"class":6},13]